- Email: [email protected]
Nederman completes Dantherm Filtration acquisition
NEWS/EXCHANGE RATES
Clean Filtration Technologies secures US$3.5mn Dow-led financing
C
lean Filtration Technologies Inc (CFT) has closed its Series B financing of US$3.5 million led by Dow Venture Capital with a US$3 million cash investment. CFT completed a US$1.5 million first round of financing earlier this year (see Filtration Industry Analyst, February 2010). The company’s CFT Turboclone filtration device is a patented water filter designed to reduce total suspended solids from difficultto-filter water. Dianne Mccord Maughon, new business development director globally for Dow Water & Process Solutions, and Christopher Jones, investment manager at Dow Venture Capital, will serve on CFT’s board of directors. Dow Water & Process Solutions (DW&PS) business has also signed a joint development agreement (JDA) with CFT. “We are excited for Dow’s continued support of the CFT Turboclone filter through its second round of financing and the JDA with DWPS. This technology has the potential to make a major and sustainable impact on the industry,” said John Mallard, CEO of Clean Filtration Technologies. “We’re looking forward to working with Dow to accelerate the commercial introduction of this exciting new technology.”
“We’re excited to help support CFT in the finance and development of this technology. Sustainability is one [of ] Dow’s core values and this technology offers the potential to further support ‘green operations’ across the industry,” said Monty Bayer, global business director, Dow Ventures & Business Development, Licensing, and Venture Capital. “This investment is strategically aligned to enable and accelerate Dow’s new business growth in the water industry.” For further information, visit www.dow.com/venture, www.dowwaterandprocess.com and www.cleanfiltration.com
Nederman completes Dantherm Filtration acquisition
N
ederman Holding AB has completed the acquisition of Dantherm Filtration from Denmark’s Dantherm A/S (see Filtration Industry Analyst, April 2010). The acquisition sees Nederman Holding double its business and become a market leader in industrial air filtration. Dantherm Filtration, which had sales of almost SEK980 million in 2009 and 900 employees, will be consolidated into Nederman from 30 April 2010. For further information, visit www.nederman.com and www.danthermfiltration.com
Exchange Rates against the US Dollar Date: 6.5.10 Country Australia
Rate A$1.12
Country Netherlands
Rate E0.79
Austria
E0.79
Norway
Belgium
E0.79
Philippines
Canada
C$1.05
Singapore
China
Yn6.83
South Africa
R7.67
DKK5.84
South Korea
KWn1140.80
Denmark
NOK6.24 Peso45.55 S$1.40
E0.79
Finland
E0.79
Spain
France
E0.79
Sweden
SEK7.69
Germany
E0.79
Switzerland
CHF1.11
Taiwan
T$31.72
Thailand
Bt32.36
India Italy
Rs45.56 E0.79
Japan
¥92.18
UK
Malaysia
Rt3.27
USA
16
Filtration Industry Analyst
£0.68 US$1.00
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Fax: +44 (0) 1865 843973 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Publisher: Greg Valero E-mail: [email protected]
Subscription Information An annual subscription to Filtration Industry Analyst includes 12 printed issues and online access for up to 5 users. Prices: 1120 for all European countries & Iran US$1256 for all countries except Europe and Japan ¥148 900 for Japan (Prices valid until 31 December 2010) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971 Email: [email protected], or via www.filtrationindustryanalyst.com. Subscriptions run for 12 months, from the date payment is received. Periodicals postage is paid at Rahway, NJ 07065, USA. Postmaster send all USA address corrections to: Filtration Industry Analyst, 365 Blair Road, Avenel, NJ 07001, USA Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/ or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Pre-press/Printed by Mayfield Press (Oxford) LImited 02207
May 2010
Clean Filtration Technologies secures US$3.5mn Dow-led financing
C
lean Filtration Technologies Inc (CFT) has closed its Series B financing of US$3.5 million led by Dow Venture Capital with a US$3 million cash investment. CFT completed a US$1.5 million first round of financing earlier this year (see Filtration Industry Analyst, February 2010). The company’s CFT Turboclone filtration device is a patented water filter designed to reduce total suspended solids from difficultto-filter water. Dianne Mccord Maughon, new business development director globally for Dow Water & Process Solutions, and Christopher Jones, investment manager at Dow Venture Capital, will serve on CFT’s board of directors. Dow Water & Process Solutions (DW&PS) business has also signed a joint development agreement (JDA) with CFT. “We are excited for Dow’s continued support of the CFT Turboclone filter through its second round of financing and the JDA with DWPS. This technology has the potential to make a major and sustainable impact on the industry,” said John Mallard, CEO of Clean Filtration Technologies. “We’re looking forward to working with Dow to accelerate the commercial introduction of this exciting new technology.”
“We’re excited to help support CFT in the finance and development of this technology. Sustainability is one [of ] Dow’s core values and this technology offers the potential to further support ‘green operations’ across the industry,” said Monty Bayer, global business director, Dow Ventures & Business Development, Licensing, and Venture Capital. “This investment is strategically aligned to enable and accelerate Dow’s new business growth in the water industry.” For further information, visit www.dow.com/venture, www.dowwaterandprocess.com and www.cleanfiltration.com
Nederman completes Dantherm Filtration acquisition
N
ederman Holding AB has completed the acquisition of Dantherm Filtration from Denmark’s Dantherm A/S (see Filtration Industry Analyst, April 2010). The acquisition sees Nederman Holding double its business and become a market leader in industrial air filtration. Dantherm Filtration, which had sales of almost SEK980 million in 2009 and 900 employees, will be consolidated into Nederman from 30 April 2010. For further information, visit www.nederman.com and www.danthermfiltration.com
Exchange Rates against the US Dollar Date: 6.5.10 Country Australia
Rate A$1.12
Country Netherlands
Rate E0.79
Austria
E0.79
Norway
Belgium
E0.79
Philippines
Canada
C$1.05
Singapore
China
Yn6.83
South Africa
R7.67
DKK5.84
South Korea
KWn1140.80
Denmark
NOK6.24 Peso45.55 S$1.40
E0.79
Finland
E0.79
Spain
France
E0.79
Sweden
SEK7.69
Germany
E0.79
Switzerland
CHF1.11
Taiwan
T$31.72
Thailand
Bt32.36
India Italy
Rs45.56 E0.79
Japan
¥92.18
UK
Malaysia
Rt3.27
USA
16
Filtration Industry Analyst
£0.68 US$1.00
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Fax: +44 (0) 1865 843973 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Publisher: Greg Valero E-mail: [email protected]
Subscription Information An annual subscription to Filtration Industry Analyst includes 12 printed issues and online access for up to 5 users. Prices: 1120 for all European countries & Iran US$1256 for all countries except Europe and Japan ¥148 900 for Japan (Prices valid until 31 December 2010) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971 Email: [email protected], or via www.filtrationindustryanalyst.com. Subscriptions run for 12 months, from the date payment is received. Periodicals postage is paid at Rahway, NJ 07065, USA. Postmaster send all USA address corrections to: Filtration Industry Analyst, 365 Blair Road, Avenel, NJ 07001, USA Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/ or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Pre-press/Printed by Mayfield Press (Oxford) LImited 02207
May 2010